Business Standard

Torrent Pharma's Dahej unit gets five US FDA observations

Observations are related to two products awaiting approvals

Torrent Power
Premium

Sohini Das Ahmedabad
The US drug regulator has issued five observations related to two products from Torrent Pharmaceuticals’ Dahej plant that are awaiting approvals. A company spokesperson confirmed the development and said they would send a reply to the US Food and Drug Administration (US FDA) within the stipulated time. Analysts say there would be no immediate impact on Torrent as these products were not to be launched immediately. 

US FDA officials visited the plant between June 26 and June 30 and issued observations related to discrepancies on batch distribution, written procedures, maintenance of equipment and criteria for sampling and testing, etc.  Analysts noted

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in